Other substances

Icosapent ethyl

A fatty acid ester.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
5
 AI-suggested references
3
 Clinical trials

General information

Icosapent ethyl on PubChem

Synonyms

Ethyl icosapentate

Marketed as

EPADEL; VASCEPA

 

Structure image - Icosapent ethyl

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC

Supporting references

Link Tested on Impact factor Notes Publication date
Superiority of cilostazol among antiplatelet FDA‐approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach
Spike protein 3CLpro Small molecule In silico Screening 		in silico 1.90

Predicted to inhibit the SARS-CoV-2 spike protein.

 Sep/27/2020

AI-suggested references

Link Publication date
Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection
Sep/02/2020
A randomized trial of icosapent ethyl in ambulatory patients with COVID-19.
Aug/26/2021
Icosapent Ethyl (Vascepa ) for the Treatment of Acute, Severe Pancreatitis.
May/15/2020
Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment
Dec/14/2020
Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach
Jan/22/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04505098 A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults Active, not recruiting Phase 4 Aug/07/2020 Feb/28/2023
  • Alternative id - 1597940
  • Interventions - Drug: Icosapent ethyl
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Kaiser Permanente Northern California, Oakland, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 39600
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of confirmed viral URIs|Percentage of patients with moderate or severe confirmed viral URIs|Worst clinical status due to a confirmed viral URI
NCT04460651 PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial Completed Phase 3 Aug/14/2020 Aug/30/2021
  • Alternative id - PREPARE-IT. Version 4.0
  • Interventions - Drug: Icosapent ethyl (IPE)|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Instituto de Investigaciones Clínicas - Rosario, Rosario, Santa Fe, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 4093
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - (A) Prevention Arm: SARS-CoV-2 positivity assesed up to day 60.|(B) Treatment Arm: COVID 19 related hospitalization (indication for hospitalization per the blinded investigator or actual hospitalization) or death assessed up to 28 days|(A) Prevention Arm: High-sensitivity C-reactive Protein (mg/dL) change from baseline to day 60 (key secondary outcome)|(A) Prevention Arm: Triglycerides (mg/dL) change from baseline to day 60|(A) Prevention Arm: FLU-PRO SCORE change from baseline to day 60 in a subset of subjects|(B) Treatment Arm: COVID 19 related hospitalization or death assessed up to 28 days (key secondary outcome)|(B) Treatment Arm: Alive and out of the hospital at 28 days.|(B) Treatment Arm: In hospital length of stay assessed up to 28 days|(B) Treatment Arm: New requirement of mechanical ventilation assed up to 28 days.|(B) Treatment Arm: Total events: non-fatal myocardial infarction or non-fatal stroke or death (initial and subsequent), until day 28.|(B) Treatment Arm: Total mortality assessed up to 28 days|(B) Treatment Arm: FLU-PRO SCORE change from baseline at 28 days
NCT04412018 An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 Completed Phase 2 Jun/04/2020 Dec/12/2020
  • Alternative id - Pro00043601
  • Interventions - Drug: Icosapent ethyl
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - North York Diagnostic and Cardiology Clinic, Toronto, Ontario, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Change in hs-CRP levels from the randomization visit (Day 1) to the Day 14 visit|Change in D-dimer levels from the randomization visit (Day 1) to the Day 14 visit|Change in erythrocyte sedimentation rate from the randomization visit (Day 1) to the Day 14 visit|Change in complete blood count from the randomization visit (Day 1) to the Day 14 visit|Change in differential count from the randomization visit (Day 1) to the Day 14 visit|Change in serum albumin levels from the randomization visit (Day 1) to the Day 14 visit|Change in neutrophil-to-lymphocyte ratio (NLR) from the randomization visit (Day 1) to the Day 14 visit|Change in systemic immune-inflammation index from the randomization visit (Day 1) to the Day 14 visit
Export (.csv)